177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03805594|
Recruitment Status : Active, not recruiting
First Posted : January 15, 2019
Last Update Posted : April 14, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Castration Levels of Testosterone Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Prostate Adenocarcinoma Stage IV Prostate Cancer Stage IVA Prostate Cancer Stage IVB Prostate Cancer||Drug: Lutetium Lu 177-PSMA-617 Biological: Pembrolizumab||Phase 1|
- To determine the recommended phase 2 dose and schedule of lutetium Lu 177-PSMA-617 (177Lu-PSMA-617) in combination with pembrolizumab in patients with metastatic castration-resistant prostate carcinoma (mCRPC). (Part A)
- To determine the objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. (Part B (Dose Expansion))
- To characterize the safety profile of the combination.
- To determine the median duration of response by RECIST 1.1 criteria.
- To determine the proportion of patients who experience >= 50% decline from baseline in serum prostate-specific antigen (PSA).
- To determine the median PSA progression-free survival.
- To determine the median time to symptomatic skeletal related event.
- To determine the 6 month radiographic progression-free survival rate and median radiographic progression-free survival.
- To determine the median overall survival.
- To assess the lesion-specific response rate by baseline PSMA avidity on gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET).
- To quantify the change from baseline in T cell repertoire, circulating T cell subsets, tumor infiltrating lymphocytes, and tumor programmed death-ligand 1 (PD-L1) expression by immunohistochemistry after one priming dose of Lu-PSMA radioligand therapy (RLT).
- To explore the relationship between timing of the 177Lu-PSMA-617 priming dose with initiation of pembrolizumab with respect to immunologic, safety, and efficacy outcomes.
- To descriptively characterize the patterns of uptake on 68Ga-PSMA-11 PET at the time of disease progression.
- To explore relationship between tumor genomic profile with clinical outcomes including response rate and progression-free survival.
- To explore the relationship between tumor dosimetry with objective response.
OUTLINE: Patients are assigned sequentially to 1 of 3 treatment schedules.
SCHEDULE 1: Patients receive lutetium Lu 177-PSMA-617 intravenously (IV) over 20-30 minutes on day 1. Beginning in cycle 2, patients receive pembrolizumab IV over 30 minutes on day 1.
SCHEDULE 2: Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes and pembrolizumab IV over 30 minutes on day 1.
SCHEDULE 3: Starting day -21, patients receive pembrolizumab IV over 30 minutes. Patients also receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1.
In all schedules, treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD) or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
After completion of study treatment, patients are followed up at 30 and 90 days.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||43 participants|
|Intervention Model:||Sequential Assignment|
|Masking:||None (Open Label)|
|Official Title:||Immunogenic Priming With PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer: A Phase 1b Study of 177Lu-PSMA-617 in Combination With Pembrolizumab|
|Actual Study Start Date :||May 10, 2019|
|Estimated Primary Completion Date :||April 30, 2024|
|Estimated Study Completion Date :||April 30, 2024|
Experimental: Schedule 1 (lutetium Lu 177-PSMA-617, pembrolizumab)
Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Beginning in cycle 2, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
Drug: Lutetium Lu 177-PSMA-617
Experimental: Schedule 2 (lutetium Lu 177-PSMA-617, pembrolizumab)
Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
Drug: Lutetium Lu 177-PSMA-617
Experimental: Schedule 3 (lutetium Lu 177-PSMA-617, pembrolizumab)
Starting day -21, patients receive pembrolizumab IV over 30 minutes. Patients also receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
Drug: Lutetium Lu 177-PSMA-617
- Recommended phase 2 dose (Part A) [ Time Frame: Through study completion of Part A of study, estimated 1 year. ]Will be determined from the aggregate of the safety and efficacy data observed graded by Common Terminology Criteria for Adverse Events (CTCAE).
- Objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (Part B) [ Time Frame: From the start of treatment until disease progression or recurrence, where the reference for progressive disease is the smallest measurements recorded from start of treatment, assessed up to 2 years ]Defined as the best response (complete response or partial response). The proportion of patients with objective response will be descriptively reported with 95% confidence interval.
- Frequency and severity of adverse events as defined by CTCAE version 4.0 [ Time Frame: Up to 90 days ]The incidence and severity of adverse events related to study treatment will be descriptively reported.
- Median duration of response by RECIST 1.1 [ Time Frame: From date of first scan indicating response until loss of response or progression, or death, whichever occurs first, assessed up to 2 years ]Will be estimated using Kaplan-Meier product limit method.
- Prostate-specific antigen (PSA) response rate [ Time Frame: Baseline up to 2 years ]The proportion of patients who achieve a greater than 50% decline from baseline PSA drawn on cycle 1 day 1 (C1D1), at any point in the treatment course, will be descriptively reported along with 95% confidence interval.
- Radiographic progression-free survival (rPFS) rate [ Time Frame: 6 months from date of first dose of study treatment ]Will be defined by RECIST version 1.1 Prostate Cancer Working Group (PCWG)3 criteria.
- Median PSA progression-free survival [ Time Frame: Up to 2 years ]Will be estimated using the Kaplan-Meier method.
- Overall survival [ Time Frame: From first date of study therapy to date of death from any cause, assessed up to 2 years ]Median overall survival and 95% confidence interval will be estimated using the Kaplan-Meier method.
- Lesion-specific response rate by baseline PSMA avidity on gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET) [ Time Frame: Baseline up to 2 years ]The median baseline uptake on Ga-PSMA-11 PET between responding versus non-responding lesions will be compared using Mann-Whitney test.
- Percent change in T cell repertoire, circulating T cell subsets, tumor infiltrating lymphocytes (TILs), and tumor PD-L1 expression by immunohistochemistry [ Time Frame: Baseline up to 2 years ]The percent change from baseline in these parameters will be reported using descriptive statistics (e.g. median, range, standard deviation).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||No|
- The subject is able and willing to comply with study procedures and provide signed and dated informed consent
- Histologically confirmed prostate adenocarcinoma. De novo small cell neuroendocrine prostate cancer will not be allowed due to putative lower PSMA expression in this tumor subtype. Treatment-emergent small cell neuroendocrine prostate cancer detected in metastatic tumor biopsy is not an exclusion
- A minimum of three PSMA-avid lesions on baseline 68Ga-PSMA-11 PET, with positive lesions defined as those with maximum standardized uptake value (SUVmax) values greater than liver.
- Progressive metastatic castration-resistant prostate cancer by Prostate Cancer Working Group (PCWG)3 criteria at the time of study entry
- Castrate level of serum testosterone at study entry (< 50 ng/dL). Patients without prior bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analogue treatment for duration of study
- Prior progression on at least one second generation androgen signaling inhibitor including abiraterone, apalutamide, darolutamide, and/or enzalutamide
- Absolute neutrophil count > 1.5 x 10^9/L
- Hemoglobin > 9.0 g/dL
- Platelet count > 100,000/microliter
- Serum creatinine =< 1.5 x upper limit of normal (ULN) or estimated glomerular filtration rate (GFR) > 50 ml/min by Cockcroft-Gault or 24 hour urine collection
- Total bilirubin =< 1.5 x ULN. In patients with known or suspected Gilbert's disease, direct bilirubin =< ULN
- Aspartate aminotransferase and alanine aminotransferase =< 2.5 x ULN (<= 5 x ULN in patients with liver metastases)
- No other systemic anti-cancer therapies administered other than LHRH analogue within 14 days, or 5 half-lives, whichever is shorter, prior to initiation of study treatment. Adverse events related to prior anti-cancer treatment other than LHRH analog treatment must have recovered to Grade <= 1 with the exception of any grade alopecia and grade <= 2 neuropathy.
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Patients must use appropriate methods of contraception during study treatment and for at least 60 days after last study treatment
- Patients who are sexually active should consider their female partner to be of childbearing potential if she has experienced menarche and is not postmenopausal (defined as amenorrhea > 24 consecutive months) or has not undergone successful surgical sterilization. Even women who use contraceptive hormones (oral, implanted, or injected), an intrauterine device, or barrier methods (diaphragms, condoms, spermicide) should be considered to be of childbearing potential
- Patients who have undergone vasectomy themselves should also be considered to be of childbearing potential
- Acceptable methods of contraception include continuous total abstinence, or double-barrier method of birth control (e.g. condoms used with spermicide, or condoms used with oral contraceptives). Periodic abstinence and withdrawal are not acceptable methods of contraception
- Patients must provide consent to comply to recommended radioprotection precautions during study
- Patients willing to undergo tumor biopsy and have at least one lesion safely accessible to tumor biopsy. Bone or soft tissue lesion is allowed
- Measurable disease by RECIST 1.1 criteria
Untreated brain metastases at study entry. Patients with previously treated brain metastases are eligible provided the following criteria are all met:
- Last treatment was > 28 days prior to cycle 1 day 1 (C1D1)
- No evidence of new/progressive brain metastases is observed on magnetic resonance imaging (MRI) obtained during screening window
- Patient is clinically stable without requirement of steroid treatment for at least 14 days prior to first dose of study treatment
- Receipt of prior PSMA-directed treatment (e.g. radiotherapy, immunotherapy, or antibody-drug conjugate)
- Prior enrollment on clinical study investigating Lu-PSMA-based radioligand therapy
- Prior treatment with radium-223 or other radioisotope for the treatment of prostate cancer
- Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=< 2 weeks of radiotherapy) to non-central nervous system (CNS) disease
- Receipt of prior pembrolizumab or another immune checkpoint inhibitor (e.g. nivolumab, ipilimumab)
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
- Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent
- Receipt of taxane chemotherapy applied in the castration-resistant setting. Prior receipt of taxane chemotherapy in the hormone-sensitive setting is allowed
- Grade > 2 peripheral neuropathy at the time of study entry
- Has severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
- Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) or treatment with drugs (e.g. neomercazole, carbimazole, etc.) that function to decrease the generation of thyroid hormone by a hyperfunctioning thyroid gland (e.g. in Graves? disease) is not considered a form of systemic treatment of an autoimmune disease
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a prednisone equivalent dose of > 10 mg daily or other form of immunosuppressive therapy within 7 days prior to first dose of study drug
- Has a history of (non-infectious) ≥ grade 2 pneumonitis/interstitial lung disease that required steroids within past 2 years or has current ≥ grade 1 pneumonitis/interstitial lung disease at the time of study enrollment..
- Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.
- Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent
Has clinically significant cardiovascular disease including, but not limited to:
- Uncontrolled or any New York Heart Association class 3 or 4 congestive heart failure
- Uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months before study entry
- Clinically significant arrhythmias not controlled by medication. Chronic rate controlled or paroxysmal atrial fibrillation/flutter is not an exclusion to study participation
- Prior external beam radiation involving >= 25% of bone marrow or within 14 days of start of protocol therapy
Major surgery within 28 days of study treatment
*Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.
- Has an active infection requiring systemic therapy
- Has a known history of human immunodeficiency virus (HIV) (screening not required)
- Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (HCV) (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection (screening not required)
- Has a known history of active Bacillus tuberculosis (TB)
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- Any condition that, in the opinion of the principal investigator, would impair the patient's ability to comply with study procedures
- History of bleeding diathesis and not currently on anti-coagulation therapy that cannot be safely discontinued for the tumor biopsy procedure
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03805594
|United States, California|
|University of California, San Francisco|
|San Francisco, California, United States, 94115|
|Principal Investigator:||Rahul Aggarwal, MD||University of California, San Francisco|
Documents provided by Rahul Aggarwal, University of California, San Francisco:
|Responsible Party:||Rahul Aggarwal, Associate Clinical Professor, University of California, San Francisco|
|Other Study ID Numbers:||
NCI-2018-02993 ( Registry Identifier: NCI Clinical Trial Reporting Program (CTRP) )
R01CA229354 ( U.S. NIH Grant/Contract )
|First Posted:||January 15, 2019 Key Record Dates|
|Last Update Posted:||April 14, 2023|
|Last Verified:||April 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Genital Neoplasms, Male
Neoplasms by Site
Genital Diseases, Male
Male Urogenital Diseases
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action